Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤SZN-8141 DUET Phase 1b first patient dosed in diabetic macular edema
- ➤DUET Phase 2a enrollment expands from approximately 60 to 150 patients
- ➤October financing generated approximately $118.9 million net proceeds
- ➤Cash runway extended into 2029, including expanded DUET study funding
- ➤Net loss reached $129.7 million, including $113.0 million non-cash losses
Expert Statements
Craig Parker, President and Chief Executive Officer of Surrozen
“We have made important progress advancing Surrozen into its next stage of development, with the first patient dosed in the SZN-8141 DUET study and plans to significantly expand Phase 2a enrollment from approximately 60 to 150 patients,”
Craig Parker, President and Chief Executive Officer of Surrozen
“The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”
First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema
DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME
Get started
Create a free account to read the full story.